MedTrace Logo

Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye

NCT06323395 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-03-21

No results posted yet for this study

Summary

The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 30 days.

Conditions

Interventions

DRUG

Vizol S LIPID BALANCE eye drops

1 drop 4 times a day

DRUG

ophthalmic saline eye drops

1 drop 4 times a day

Sponsors & Collaborators

  • Poseidon CRO

    collaborator INDUSTRY

  • Jadran Galenski laboratorij d.d.

    lead INDUSTRY

Principal Investigators

  • D. Veselinović, prof. dr. · Specialized clinic for eye desease - klinika Veselinović

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06323395 on ClinicalTrials.gov